Omeros (OMER) Return on Sales (2010 - 2026)

Omeros (OMER) posted Return on Sales of 0.0% for Q1 2026, up 231.32% sequentially from 0.0% in Q1 2025, and up 1.0% YoY from 0.0% in Q1 2025.

Omeros (OMER) Return on Sales (2010 - 2026) Analysis & Trends

Omeros has reported Return on Sales for 15 years, with the latest figure at 0.0% in Q1 2026.

Quarterly Return on Sales rose 1.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0% (changed 0.0% YoY) and the FY2020 annual result came in at 0.0%, changed 0.0% from the prior year.
Return on Sales grew to 0.0% in Q1 2026 per OMER's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 0.01% in Q2 2022 and troughed at 0.0% in Q1 2025.
A 3-year average of 0.01% and a median of 0.01% in 2022 frame the typical range for Return on Sales.
The sharpest annual moves came in 2022 and 2026: Return on Sales changed 0 bps in 2022, then rose 1 bps in 2026.
Over 3 years, Return on Sales stood at 0.01% in 2022, then slumped by 134 bps to 0.0% in 2025, then surged by 231 bps to 0.0% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 0.01% for Q1 2026, Q1 2025, and Q2 2022 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	0.00%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	0.00%
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	0.00%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	0.00%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	0.00%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	0.00%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	0.00%
10	Omeros	1.24 Bn	1.24 Bn	27.73 Mn	0.00%

Download Data